Back to partners

Abiomed

Corporate partner

Abiomed

Abiomed was founded in 1981 for the purpose of developing the world's first artificial heart. This interactive timeline shows how Abiomed’s mission evolved to focus on native heart recovery. Through its history, Abiomed has been dedicated to bringing the most advanced and innovative technology to patients and physicians.

Over the last five years, the company has invested more than $850 million on clinical research. Abiomed has seven completed FDA studies and five post-market approval studies that validate Impella® heart pumps are safe and effective for high-risk PCI, cardiogenic shock, and right heart failure. Impella heart pumps are included in 13 clinical guidelines and more than 1,200 peer-reviewed clinical publications.